Last reviewed · How we verify
Lamictal®
At a glance
| Generic name | Lamictal® |
|---|---|
| Also known as | Lamotrigine (generic name for Lamictal®), Carbamazepine (generic name for Tegretol®), Lamotrigine, the reference product |
| Sponsor | Teva Pharmaceuticals USA |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Lamotrigine 25 mg Chewable Tablets, Fasting (PHASE1)
- Lamotrigine 25 mg Chewable Tablets, Non-Fasting (PHASE1)
- Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions (PHASE1)
- Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions (PHASE1)
- Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg (PHASE1)
- Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg (PHASE1)
- Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg (PHASE1)
- Excessive Crying in Children With Cerebral Palsy and Communication Deficits (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamictal® CI brief — competitive landscape report
- Lamictal® updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI